StreetInsider.com News Articles

Waters Corp. (WAT) PT Raised to $450 at Bernstein SocGen Group

Wed, 05 Aug 2026 09:23:10 -0400

Bernstein SocGen Group analyst Eve Burstein raised the price target on Waters Corp. (NYSE: WAT) to $450.00 (from $435.00) while maintaining a Outperform rating.

Waters Corp. (WAT) PT Raised to $420 at Stifel

Wed, 05 Aug 2026 08:25:29 -0400

Stifel analyst Daniel Arias raised the price target on Waters Corp. (NYSE: WAT) to $420.00 (from $380.00) while maintaining a Hold rating.

Waters Corp. (WAT) PT Raised to $400 at Wells Fargo

Wed, 05 Aug 2026 07:58:05 -0400

Wells Fargo analyst Evan Stampler raised the price target on Waters Corp. (NYSE: WAT) to $400.00 (from $370.00) while maintaining a Equal Weight rating.

Waters Corp. (WAT) PT Raised to $475 at RBC Capital

Wed, 05 Aug 2026 07:54:40 -0400

RBC Capital analyst Dan Leonard raised the price target on Waters Corp. (NYSE: WAT) to $475.00 (from $435.00) while maintaining a Outperform rating.

TD Cowen Upgrades Waters Corp. (WAT) to Buy

Wed, 05 Aug 2026 05:32:26 -0400

TD Cowen analyst Dan Brennan upgraded Waters Corp. (NYSE: WAT) from Hold to Buy with a price target of $475.00 (from $408.00).

The analyst comments "We upgrade WAT to Buy post 2Q. What's changed? 1) Core WAT delivered another solid result & we expect HSD% growth to continue with the instrument replacement cycle extending into '28; 2) BDX beat cons. & confidence is rising for the ramp (organic, synergies) ahead. With industry-leading growth, upside levers intact & early BD traction we think a premium multiple can be supported – PT to $475."

For an analyst ratings summary and ratings history on Waters

TD Cowen Upgrades Waters Corp. (WAT) to Buy

Wed, 05 Aug 2026 05:32:26 -0400

TD Cowen analyst Dan Brennan upgraded Waters Corp. (NYSE: WAT) from Hold to Buy with a price target of $475.00 (from $408.00).

For an analyst ratings summary and ratings history on Waters

TD Cowen Upgrades Waters Corp. (WAT) to Buy

Wed, 05 Aug 2026 05:32:26 -0400

TD Cowen analyst Dan Brennan upgraded Waters Corp. (NYSE: WAT) from Hold to Buy with a price target of $475.00 (from $408.00).

For an analyst ratings summary and ratings history on Waters

Waters Corp. (WAT) PT Raised to $460 at Barclays

Wed, 05 Aug 2026 04:30:19 -0400

Barclays analyst Luke Sergott raised the price target on Waters Corp. (NYSE: WAT) to $460.00 (from $425.00) while maintaining a Overweight rating.

Waters Corp. (WAT) PT Raised to $455 at Jefferies

Tue, 04 Aug 2026 17:05:42 -0400

Jefferies analyst Tycho Peterson raised the price target on Waters Corp. (NYSE: WAT) to $455.00 (from $450.00) while maintaining a Buy rating.

Form 8-K WATERS CORP /DE/ For: Aug 04

Tue, 04 Aug 2026 06:10:00 -0400

si-local-file:///var/storage/secattach/20260804/26860857.html

Form 8-K WATERS CORP /DE/ For: Aug 04

Tue, 04 Aug 2026 06:10:00 -0400

si-local-file:///var/storage/secattach/20260804/26860857.html

Waters Corp. (WAT) Tops Q2 EPS by 4c ; Offers Guidance

Tue, 04 Aug 2026 06:06:23 -0400

Waters Corp. (NYSE: WAT) reported Q2 EPS of $3.05, $0.04 better than the analyst estimate of $3.01. Revenue for the quarter came in at $1.64 billion versus the consensus estimate of $1.62 billion.

GUIDANCE:

Waters Corp. sees FY2026 EPS of $14.45-$14.65, versus the consensus of $14.51. Waters Corp. sees FY2026 revenue of $6.41-6.47 billion, versus the consensus of $6.44 billion.

Waters Corp. sees Q3 2026 EPS of $3.95-$4.05, versus the consensus of $3.99. Waters Corp. sees Q3 2026 revenue of $1.74-1.76 billion, versus the consensus of $1.75 billion.

For earnings history and earnings-related data on Waters Corp. (WAT) click here.

Waters Corp. (WAT) Tops Q2 EPS by 4c ; Offers Guidance

Tue, 04 Aug 2026 06:06:23 -0400

Waters Corp. (NYSE: WAT) reported Q2 EPS of $3.05, $0.04 better than the analyst estimate of $3.01. Revenue for the quarter came in at $1.64 billion versus the consensus estimate of $1.62 billion.

GUIDANCE:

Waters Corp. sees FY2026 EPS of $14.45-$14.65, versus the consensus of $14.51. Waters Corp. sees FY2026 revenue of $6.41-6.47 billion, versus the consensus of $6.44 billion.

Waters Corp. sees Q3 2026 EPS of $3.95-$4.05, versus the consensus of $3.99. Waters Corp. sees Q3 2026 revenue of $1.74-1.76 billion, versus the consensus of $1.75 billion.

For earnings history and earnings-related data on Waters Corp. (WAT) click here.

Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results

Tue, 04 Aug 2026 06:00:00 -0400

Second Quarter 2026 Highlights

Total reported revenue of $1.645 billion surpassed the high end of the guidance range, driven by broad-based outperformance across both organic revenue and the acquired businesses.
Organic revenue of $828 million grew 7% as reported and 9% in constant currency; the Analytical Sciences Division (ASD) delivered 8% instrument growth and double-digit chemistry consumables growth, led by low-double-digit growth in both Pharma and A&G end markets, in constant currency, as the market recovery has entered a broader phase, expanding across additional customer segments.
Biosciences and Diagnostic Solutions revenue of $817 million exceeded guidance by $15 million and grew

Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results

Tue, 04 Aug 2026 06:00:00 -0400

Second Quarter 2026 Highlights
Total reported revenue of $1.645 billion surpassed the high end of the guidance range, driven by broad-based outperformance across both organic revenue and the acquired businesses.
Organic revenue of $828 million grew 7% as reported and 9% in constant currency; the Analytical Sciences Division (ASD) delivered 8% instrument growth and double-digit chemistry consumables growth, led by low-double-digit growth in both Pharma and A&G end markets, in constant currency, as the market recovery has entered a broader phase, expanding across additional customer segments.
Biosciences and Diagnostic Solutions revenue of $817 million exceeded guidance by $15 million and grew

Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results

Tue, 04 Aug 2026 06:00:00 -0400

Second Quarter 2026 Highlights
Total reported revenue of $1.645 billion surpassed the high end of the guidance range, driven by broad-based outperformance across both organic revenue and the acquired businesses.
Organic revenue of $828 million grew 7% as reported and 9% in constant currency; the Analytical Sciences Division (ASD) delivered 8% instrument growth and double-digit chemistry consumables growth, led by low-double-digit growth in both Pharma and A&G end markets, in constant currency, as the market recovery has entered a broader phase, expanding across additional customer segments.
Biosciences and Diagnostic Solutions revenue of $817 million exceeded guidance by $15 million and grew

Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results

Tue, 04 Aug 2026 06:00:00 -0400

Second Quarter 2026 Highlights
Total reported revenue of $1.645 billion surpassed the high end of the guidance range, driven by broad-based outperformance across both organic revenue and the acquired businesses.
Organic revenue of $828 million grew 7% as reported and 9% in constant currency; the Analytical Sciences Division (ASD) delivered 8% instrument growth and double-digit chemistry consumables growth, led by low-double-digit growth in both Pharma and A&G end markets, in constant currency, as the market recovery has entered a broader phase, expanding across additional customer segments.
Biosciences and Diagnostic Solutions revenue of $817 million exceeded guidance by $15 million and grew

Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results

Tue, 04 Aug 2026 06:00:00 -0400

Second Quarter 2026 Highlights
Total reported revenue of $1.645 billion surpassed the high end of the guidance range, driven by broad-based outperformance across both organic revenue and the acquired businesses.
Organic revenue of $828 million grew 7% as reported and 9% in constant currency; the Analytical Sciences Division (ASD) delivered 8% instrument growth and double-digit chemistry consumables growth, led by low-double-digit growth in both Pharma and A&G end markets, in constant currency, as the market recovery has entered a broader phase, expanding across additional customer segments.
Biosciences and Diagnostic Solutions revenue of $817 million exceeded guidance by $15 million and grew

Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results

Tue, 04 Aug 2026 06:00:00 -0400

Second Quarter 2026 Highlights
Total reported revenue of $1.645 billion surpassed the high end of the guidance range, driven by broad-based outperformance across both organic revenue and the acquired businesses.
Organic revenue of $828 million grew 7% as reported and 9% in constant currency; the Analytical Sciences Division (ASD) delivered 8% instrument growth and double-digit chemistry consumables growth, led by low-double-digit growth in both Pharma and A&G end markets, in constant currency, as the market recovery has entered a broader phase, expanding across additional customer segments.
Biosciences and Diagnostic Solutions revenue of $817 million exceeded guidance by $15 million and grew

Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results

Tue, 04 Aug 2026 06:00:00 -0400

Second Quarter 2026 Highlights
Total reported revenue of $1.645 billion surpassed the high end of the guidance range, driven by broad-based outperformance across both organic revenue and the acquired businesses.
Organic revenue of $828 million grew 7% as reported and 9% in constant currency; the Analytical Sciences Division (ASD) delivered 8% instrument growth and double-digit chemistry consumables growth, led by low-double-digit growth in both Pharma and A&G end markets, in constant currency, as the market recovery has entered a broader phase, expanding across additional customer segments.
Biosciences and Diagnostic Solutions revenue of $817 million exceeded guidance by $15 million and grew

Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results

Tue, 04 Aug 2026 06:00:00 -0400

Second Quarter 2026 Highlights
Total reported revenue of $1.645 billion surpassed the high end of the guidance range, driven by broad-based outperformance across both organic revenue and the acquired businesses.
Organic revenue of $828 million grew 7% as reported and 9% in constant currency; the Analytical Sciences Division (ASD) delivered 8% instrument growth and double-digit chemistry consumables growth, led by low-double-digit growth in both Pharma and A&G end markets, in constant currency, as the market recovery has entered a broader phase, expanding across additional customer segments.
Biosciences and Diagnostic Solutions revenue of $817 million exceeded guidance by $15 million and grew

Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results

Tue, 04 Aug 2026 06:00:00 -0400

Second Quarter 2026 Highlights
Total reported revenue of $1.645 billion surpassed the high end of the guidance range, driven by broad-based outperformance across both organic revenue and the acquired businesses.
Organic revenue of $828 million grew 7% as reported and 9% in constant currency; the Analytical Sciences Division (ASD) delivered 8% instrument growth and double-digit chemistry consumables growth, led by low-double-digit growth in both Pharma and A&G end markets, in constant currency, as the market recovery has entered a broader phase, expanding across additional customer segments.
Biosciences and Diagnostic Solutions revenue of $817 million exceeded guidance by $15 million and grew

Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results

Tue, 04 Aug 2026 06:00:00 -0400

Second Quarter 2026 Highlights
Total reported revenue of $1.645 billion surpassed the high end of the guidance range, driven by broad-based outperformance across both organic revenue and the acquired businesses.
Organic revenue of $828 million grew 7% as reported and 9% in constant currency; the Analytical Sciences Division (ASD) delivered 8% instrument growth and double-digit chemistry consumables growth, led by low-double-digit growth in both Pharma and A&G end markets, in constant currency, as the market recovery has entered a broader phase, expanding across additional customer segments.
Biosciences and Diagnostic Solutions revenue of $817 million exceeded guidance by $15 million and grew

Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results

Tue, 04 Aug 2026 06:00:00 -0400

Second Quarter 2026 Highlights
Total reported revenue of $1.645 billion surpassed the high end of the guidance range, driven by broad-based outperformance across both organic revenue and the acquired businesses.
Organic revenue of $828 million grew 7% as reported and 9% in constant currency; the Analytical Sciences Division (ASD) delivered 8% instrument growth and double-digit chemistry consumables growth, led by low-double-digit growth in both Pharma and A&G end markets, in constant currency, as the market recovery has entered a broader phase, expanding across additional customer segments.
Biosciences and Diagnostic Solutions revenue of $817 million exceeded guidance by $15 million and grew

Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results

Tue, 04 Aug 2026 06:00:00 -0400

Second Quarter 2026 Highlights
Total reported revenue of $1.645 billion surpassed the high end of the guidance range, driven by broad-based outperformance across both organic revenue and the acquired businesses.
Organic revenue of $828 million grew 7% as reported and 9% in constant currency; the Analytical Sciences Division (ASD) delivered 8% instrument growth and double-digit chemistry consumables growth, led by low-double-digit growth in both Pharma and A&G end markets, in constant currency, as the market recovery has entered a broader phase, expanding across additional customer segments.
Biosciences and Diagnostic Solutions revenue of $817 million exceeded guidance by $15 million and grew